Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 815 results for "gilead sciences"

Express Scripts to cover AbbVie hepatitis C drug, drops Gilead treatment
Social Dashboard

Lawsuit Alleges Price Gouging by Maker of Hepatitis Drug

Ever since Gilead Sciences began selling its Sovaldi hepatitis C treatment, there has been controversy over the price. And at one point, the nation's biggest pharmacy benefit manager urged companies and health plans to switch to medicines made by ... Austin American Statesman, 3 days ago

156 images for gilead sciences

Bidness Etc, 5 days ago
Bio Spectrum Asia, 4 days ago
American Banking News, 1 week ago
French Tribune, 2 weeks ago, 1 week ago, 1 week ago
Bidness Etc, 1 week ago
Bidness Etc, 2 weeks ago
Bidness Etc, 2 weeks ago
Bidness Etc, 2 weeks ago

Gilead Sciences, Inc. Gets Some Competition (but Not Really)

So much for the potential price war in the hepatitis C market. For now, at least. AbbVie ( NYSE: ABBV ) gained Food and Drug Administration approval for its new hepatitis C cocktail, dubbed Viekira Pak, on Friday, and priced the regimen at ...
 Motley Fool8 hours ago New rival to Gilead hepatitis C drug approved  SiliconValley.com2 days ago New Hepatitis C Drug Gets Helping Hand  Austin American Statesman2 hours ago AbbVie receives approval for hepatitis C treatment  Taipei Times Online1 day ago
Motley Fool

These Biotech Stocks Are Growing Even Faster Than Gilead Sciences

Thanks to billions of dollars in new revenue from recently launched hepatitis C drugs, Gilead Sciences ( NASDAQ: GILD ) sales surged 117% year over year during the third quarter. That's impressive growth by any measure, but investors might be ...
 Motley Fool18 hours ago
Pharma Letter

Ono Pharmaceutical signs licensing agreement with Gilead Sciences

Ono Pharmaceutical Co., Ltd. (Ono), a Japan-based pharmaceutical company, has entered into an exclusive license agreement with Gilead Sciences, Inc. for the development and commercialization of ONO-4059, ONO's oral Bruton's tyrosine kinase (BTK) ...
 Individual.com2 days ago Gilead teams up with Ono to develop cancer med  Seeking Alpha2 days ago Gilead Sciences And Ono Pharma Collaborate On Global Development Of ONO-4059  RTTNews.com3 days ago Ono Pharmaceutical Company, Ltd. And Gilead Sciences, Inc. Announce Exclusive License Agreement To Develop BTK Inhibitor, ONO-4059, For The Treatment Of B-Cell Malignancies And Other Diseases  BioSpace2 days ago
Seeking Alpha

Gilead: What's Ahead In 2015 For This Biotech Juggernaut

Summary Biotech juggernaut Gilead Sciences has provided its shareholders with better than a 30% gain in 2014 so far as we head into the end of the year. Although the stock has spent the last three months consolidating those gains in a relatively ...
 Seeking Alpha1 day ago
Schaeffers Research

Analyst Update: Gilead Sciences, Inc., Hasbro, Inc., and Mattel, Inc.

Analysts are weighing in today on drug issue Gilead Sciences, Inc. (NASDAQ:GILD), as well as toymakers Hasbro, Inc. (NASDAQ:HAS) and Mattel, Inc. (NASDAQ:MAT). Here's a quick look at today's brokerage notes on GILD, HAS,
 Schaeffers Research2 days ago AbbVie to Sell Hepatitis C Drug at 12% Discount to Gilead Rival  Washington Post2 days ago Biotech Predictions for Large Cap Firms Include Medivation, Inc., Gilead Sciences, Inc.  BioSpace3 days ago Gilead Sciences Inc. (GILD) Pops 2.76% for December 19  Equities.com2 days ago
Bidness Etc

Wishing, hoping, planning as AbbVie's hep C do-or-die moment nears

As 2014 winds down, and Gilead Sciences ($GILD) keeps winding up hep C sales by the billion, AbbVie ($ABBV) waits, vibrating with anticipation. Its three-drug cocktail is up for FDA approval any day now, and the Illinois-based company is ready to ...
 FiercePharma3 days ago Abbvie's Hep C Regimen Approved, Marketing Battle With Gilead Up Next  TheStreet.com2 days ago UPDATED: AbbVie wins blockbuster hep C approval, but shuns a deep discount on price  FierceBiotech1 day ago U.S. FDA approves Gilead's $94,500 hepatitis C drug  Reuters2 months ago
American Banking News

Shares of Gilead Sciences Receive a Boost, Up 2.4%

One of today's stocks on the move is Gilead Sciences (NASDAQ:GILD), up 2.4% to $104.84. The S&P is currently trading 1.4% higher to 2,041 and the Dow Jones Industrial Average is trading 1.4% higher
 Individual.com3 days ago Argus Increases Gilead Sciences Price Target to $130.00 (GILD)  Mideast Time1 week ago Argus Boosts Gilead Sciences Price Target to $130.00 (GILD)  American Banking News1 week ago Gilead Sciences Given New $130.00 Price Target at Argus (GILD)  SleekMoney1 week ago

Ho Ho Harvoni: Gilead Sciences Is A Gift That Should Be Under Every Investor's Tree.

Summary Whether you're a value or a growth investor, GILD belongs in your portfolio. Gilead Sciences is at the forefront of worldwide HCV eradication with its combination tablet: Harvoni. Regardless of anticipated competition, Gilead is a rapidly ...
 Seeking Alpha3 days ago
Seeking Alpha

Gilead Sciences Stands Alone

Summary A relatively straightforward screen meant to help me find attractive growth stocks located only one result: Gilead Sciences. Although I have had mixed feelings about Gilead in the past, it compares favorably to wide variety of similar ...
 Seeking Alpha4 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - gilead sciences
Get updated on latest news & your favorite topics right in your inbox!
More     Less